Concurrent with this FDA approval – the fifth for CYRAMZA – the FDA has also removed the boxed warning from the CYRAMZA labeling. HCC is the most common
The designation has been granted for Pomalyst to treat patients with HIV-positive Kaposi sarcoma who have previously received systemic chemotherapy, in addition to patients with HIV‐negative Kaposi’s sarcoma.
Pfizer’s Andover site houses commercial manufacturing and product development functions, with colleagues dedicated to the development and production of high-quality complex biologics and vaccines. With its modular and
The study has showed a significantly higher proportion of patients with resistant hypertension (RHTN) and CKD taking Veltassa remained on spironolactone therapy compared against patients taking placebo at
The phase 3 CheckMate -498 trial assessing Opdivo plus radiation against temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM) did not achieve
Under the terms of the agreement, Pfizer will acquire Therachon for $340m upfront with an additional $470m in additional payments contingent on the achievement of key milestones in
As per terms of the agreement, Takeda is also eligible to secure up to an additional $1.9bn in potential milestone payments from Novartis along with $3.4bn upfront payment
“Pfizer has worked to pioneer biomarker-driven medicine for patients with ALK-positive non-small cell lung cancer and we continue to advance patient care with the approval of LORVIQUA,” said
The trial results demonstrated a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Calquence monotherapy compared against a combination regimen of rituximab plus physician’s choice of idelalisib
Since PharmaCyte’s last press release describing the manufacturing process for its clinical trial product and the testing of that product, the data from the manufacturing process has been
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.